{"ts": 1769396036.258469, "content": "PMC-402 Indications Solid tumors Mechanism of action / Target PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment (TME). Status An increase in T cell activity along with a shift in polarization from M2 to M1 macrophages have been identified in the in an vitro study. PharmAbcine initiated the GLP-tox study of PMC-402 in 1Q21 and expects an IND filing in 3Q22. Publications * The preclinical data presentation at AACR 2020 Olinvacimab PMC-309 PMC-402 PMC-403 LinkedIn I Facebook I YouTube 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea HQ +82-42-863-2017 R&D Center +82-42-861-2017 FAX +82-42-863-2080 COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.", "type": "text"}